These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 24778399)

  • 1. 2013 update of the American Society of Clinical Oncology/College of American Pathologists guideline for human epidermal growth factor receptor 2 testing: impact on immunohistochemistry-negative breast cancers.
    Lambein K; Van Bockstal M; Denys H; Libbrecht L
    J Clin Oncol; 2014 Jun; 32(17):1856-7. PubMed ID: 24778399
    [No Abstract]   [Full Text] [Related]  

  • 2. Interpretation of human epidermal growth factor receptor 2 (HER2) in situ hybridization assays using 2013 update of American Society of Clinical Oncology/College of American Pathologists HER2 Guidelines.
    Bhargava R; Dabbs DJ
    J Clin Oncol; 2014 Jun; 32(17):1855. PubMed ID: 24778404
    [No Abstract]   [Full Text] [Related]  

  • 3. Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer.
    Shah SS; Ketterling RP; Goetz MP; Ingle JN; Reynolds CA; Perez EA; Chen B
    Hum Pathol; 2010 Jan; 41(1):103-6. PubMed ID: 19762065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reply to R. Bhargava et al and K. Lambein et al.
    Wolff AC; Hammond ME; Hicks DG; Dowsett M; Hayes DF; McShane LM
    J Clin Oncol; 2014 Jun; 32(17):1857-9. PubMed ID: 24778389
    [No Abstract]   [Full Text] [Related]  

  • 5. The American Society of Clinical Oncology-College of American Pathologists Guideline Update for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer.
    Schnitt SJ; Tarantino P; Collins LC
    Arch Pathol Lab Med; 2023 Sep; 147(9):991-992. PubMed ID: 37303241
    [No Abstract]   [Full Text] [Related]  

  • 6. American Society of Clinical Oncology/College of American Pathologists Human Epidermal Growth Factor Receptor 2 Testing Clinical Practice Guideline Upcoming Modifications: Proof That Clinical Practice Guidelines Are Living Documents.
    Hammond ME; Hicks DG
    Arch Pathol Lab Med; 2015 Aug; 139(8):970-1. PubMed ID: 25884371
    [No Abstract]   [Full Text] [Related]  

  • 7. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.
    Lim TH; Lim AS; Thike AA; Tien SL; Tan PH
    Arch Pathol Lab Med; 2016 Feb; 140(2):140-7. PubMed ID: 26910218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Analysis of Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer According to 2007 and 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations.
    Hanna WM; Slodkowska E; Lu FI; Nafisi H; Nofech-Mozes S
    J Clin Oncol; 2017 Sep; 35(26):3039-3045. PubMed ID: 28445098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. National guidelines and level of evidence: comments on some of the new recommendations in the American Society of Clinical Oncology and the College of American Pathologists human epidermal growth factor receptor 2 guidelines for breast cancer.
    Rakha EA; Pigera M; Shaaban A; Shin SJ; D'Alfonso T; Ellis IO; Lee AH
    J Clin Oncol; 2015 Apr; 33(11):1301-2. PubMed ID: 25753440
    [No Abstract]   [Full Text] [Related]  

  • 10. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers.
    Singh K; Tantravahi U; Lomme MM; Pasquariello T; Steinhoff M; Sung CJ
    Breast Cancer Res Treat; 2016 Jun; 157(3):405-11. PubMed ID: 27180259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementation of the 2018 Human Epidermal Growth Factor Receptor 2 Guideline by American Society of Clinical Oncology/College of American Pathologists Will Reduce False-Positive Tests.
    Martin V; Valera A; De Joffrey M; Banfi S; Mazzucchelli L
    Arch Pathol Lab Med; 2019 Apr; 143(4):411-412. PubMed ID: 30605369
    [No Abstract]   [Full Text] [Related]  

  • 12. Human Epidermal Growth Factor Receptor 2 Testing by Fluorescent In Situ Hybridization: Positive or Negative? American Society of Clinical Oncology/College of American Pathologists Guidelines 2007, 2013, and 2018.
    Murray C; D'Arcy C; Gullo G; Flanagan L; Quinn CM
    Arch Pathol Lab Med; 2019 Apr; 143(4):412-413. PubMed ID: 30605368
    [No Abstract]   [Full Text] [Related]  

  • 13. Impact of the 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing of invasive breast carcinoma: a focus on tumours assessed as 'equivocal' for HER2 gene amplification by fluorescence in-situ hybridization.
    Bethune GC; Veldhuijzen van Zanten D; MacIntosh RF; Rayson D; Younis T; Thompson K; Barnes PJ
    Histopathology; 2015 Dec; 67(6):880-7. PubMed ID: 25913507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
    Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
    Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
    Collins LC; Martyniak A; Kandel MJ; Stadler ZK; Masciari S; Miron A; Richardson AL; Schnitt SJ; Garber JE
    Am J Surg Pathol; 2009 Jul; 33(7):1093-7. PubMed ID: 19390427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline.
    Fan YS; Casas CE; Peng J; Watkins M; Fan L; Chapman J; Ikpatt OF; Gomez C; Zhao W; Reis IM
    Breast Cancer Res Treat; 2016 Feb; 155(3):457-62. PubMed ID: 26895325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ASCO-CAP guidelines for breast predictive factor testing: an update.
    Hammond ME
    Appl Immunohistochem Mol Morphol; 2011 Dec; 19(6):499-500. PubMed ID: 22089488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers.
    Tchrakian N; Flanagan L; Harford J; Gannon JM; Quinn CM
    Virchows Arch; 2016 Feb; 468(2):207-11. PubMed ID: 26521061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. erbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line.
    Ethier SP; Kokeny KE; Ridings JW; Dilts CA
    Cancer Res; 1996 Feb; 56(4):899-907. PubMed ID: 8631031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: impact of 2007 American Society of Clinical Oncology/College of American Pathologists criteria.
    Schalper KA; Kumar S; Hui P; Rimm DL; Gershkovich P
    Arch Pathol Lab Med; 2014 Feb; 138(2):213-9. PubMed ID: 24164555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.